Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis

JJ Biagi, MJ Raphael, WJ Mackillop, W Kong, WD King… - Jama, 2011 - jamanetwork.com
Context Adjuvant chemotherapy (AC) improves survival among patients with resected
colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown …

Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation

JJ Biagi, JF Seymour - Blood, The Journal of the American …, 2002 - ashpublications.org
Incidence rates of follicular lymphoma (FL) inexplicably vary markedly between Western and
Asian countries. A hallmark of FL is the bcl-2 translocation, characterized by 1 of 2 common …

The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis

MJ Raphael, JJ Biagi, W Kong, M Mates… - Breast cancer research …, 2016 - Springer
Background It is known that adjuvant chemotherapy improves survival in women with breast
cancer. It is not known whether the interval between surgery and the initiation of …

[HTML][HTML] FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer

T Conroy, P Hammel, M Hebbar… - … England Journal of …, 2018 - Mass Medical Soc
Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer …

Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial

T Conroy, F Castan, A Lopez, A Turpin… - JAMA …, 2022 - jamanetwork.com
Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …

Unicancer GI PRODIGE 24/CCTG PA. 6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients …

T Conroy, P Hammel, M Hebbar, M Ben Abdelghani… - 2018 - ascopubs.org
LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in
metastatic pancreatic cancer for patients (pts) with good performance status. This trial …

[HTML][HTML] A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

JJ Biagi, AM Oza, HI Chalchal, R Grimshaw, SL Ellard… - Annals of …, 2011 - Elsevier
Purpose Sunitinib is a multitargeted receptor tyrosine kinase inhibitor. We conducted a two-
stage phase II study to evaluate the objective response rate of oral sunitinib in recurrent …

The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review

D Quan, S Gallinger, C Nhan, RA Auer, JJ Biagi… - Surgery, 2012 - Elsevier
BACKGROUND: To determine the role of liver resection in patients with liver and
extrahepatic colorectal cancer metastases and the role of chemotherapy in patients in …

Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)

MG Penniment, PB De Ieso, JA Harvey… - The lancet …, 2018 - thelancet.com
Background A short course of radiotherapy is commonly prescribed for palliative relief of
malignant dysphagia in patients with incurable oesophageal cancer. We compared …

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

KKW Chan, H Guo, S Cheng, JM Beca… - Cancer …, 2020 - Wiley Online Library
Abstract Background In Ontario, FOLFIRINOX (FFX) and gemcitabine+ nab‐paclitaxel (GnP)
have been publicly funded for first‐line unresectable locally advanced pancreatic cancer …